Pricing Log in Create free account

Taysha Gene Therapies, Inc. (TSHA) vs Urogen Pharma (URGN)

Taysha Gene Therapies, Inc. and Urogen Pharma are both Biotechnology companies. Taysha Gene Therapies, Inc. and Urogen Pharma are of similar size ($1.3B and $1.3B). Urogen Pharma grew revenue faster over the last twelve months: 159.3% against 19.0%. Taysha Gene Therapies, Inc. has the higher net margin (0.00% vs −26.3%) and the higher return on invested capital (0.00% vs 0.00%). Across the 15 metrics below, Urogen Pharma leads on 8 and Taysha Gene Therapies, Inc. on 7.

Valuation

Metric TSHA URGN Biotechnology median
P/E n/m n/m 10.60
P/S 136.10 5.01 9.40
P/B 4.15 n/m 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 101.67 5.41 9.02
Earnings yield (9.66%) (5.32%) (32.88%)
Free cash flow yield (8.66%) (10.53%) (23.13%)

Profitability

Metric TSHA URGN Biotechnology median
Gross margin 100.00% 91.41% 68.51%
Operating margin 0.00% (12.36%) 0.00%
Net margin 0.00% (26.27%) 0.00%
Free cash flow margin 0.00% (52.77%) 0.00%
Return on equity (47.05%) 54.65% (51.96%)
Return on assets (37.23%) (28.78%) (46.06%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric TSHA URGN Biotechnology median
Revenue growth (TTM) 18.96% 159.29% 6.76%
EPS growth (last fiscal year) 5.56% (7.77%) 29.88%
Revenue growth, 5-year CAGR — 56.22% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric TSHA URGN Biotechnology median
Debt to equity 0.13 (1.53) 0.00
Current ratio 17.76 3.40 4.97
Net debt to EBITDA 2.47 0.00 1.01

Dividend

Metric TSHA URGN Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric TSHA URGN Biotechnology median
Market cap 1.33b 1.26b 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack